First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer
Click Here to Manage Email Alerts
The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer.
Lurbinectedin (Zepzelca; Jazz Pharmaceuticals, PharmaMar) is an RNA polymerase II inhibitor. Atezolizumab (Tecentriq, Genentech) is an anti-PD-L1 antibody.
The randomized phase 3 IMforte trial included adults with extensive-stage small cell lung cancer who had ongoing response or stable disease after induction therapy with four cycles of carboplatin, etoposide and atezolizumab.
Researchers randomly assigned half of the trial participants to standard first-line maintenance with atezolizumab. The other half received lurbinectedin plus atezolizumab.
Results showed statistically significant improvement in OS and PFS — the study’s primary endpoints — with the combination, according to a Jazz Pharmaceuticals press release.
"These results demonstrate the potential of this regimen to delay disease progression and extend survival for patients with this aggressive disease,” Rob Iannone, MD, MSCE, executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals, said in the release. “We are pleased with these clinically meaningful results and plan to submit a supplemental new drug application in the first half of 2025 to support this combination in the first-line maintenance setting.”
Preliminary safety data showed the combination exhibited a safety profile consistent with the known safety profiles of the individual agents, according to the release. Researchers observed no new safety signals.
Complete data from the IMforte trial will be presented at a medical meeting.
Read more about
Click Here to Manage Email Alerts